Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>Aspira Women’s Health reported 3Q23 financial results, mostly in line with our estimates.</li><li>Revenue of $2.2 million was below our estimate, but good expense control is in place and is expected to continue.</li><li>Our estimates for 2023 and 2024 remain in line with our prior estimates.</li></ul>

Aspira Women’s Health reported 3Q23 financial results, mostly in line with our estimates.Revenue of $2.2 million was below our estimate, but good expense control is in place and is expected to continue.Our estimates for 2023 and 2024 remain in line with our prior estimates.

Aspira Women's Health, Inc. - Reports 3Q23 Results

<ul><li>On October 25, Aspira Women’s Health announced that a poster on its in-development miRNA-based ovarian cancer test was presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Ovarian Cancer.</li><li>The poster, titled, “Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model,” highlighted data showing miRNA’s potential to improve the diagnostic accuracy of non-invasive diagnostic tests.</li><li>The study showed that the addition of miRNA improved the detection of early-stage ovarian cancers and that diagnostic performance improved even further when using a combination of approaches, including miRNA, proteins, and metadata. </li></ul>

On October 25, Aspira Women’s Health announced that a poster on its in-development miRNA-based ovarian cancer test was presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Ovarian Cancer.The poster, titled, “Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model,” highlighted data showing miRNA’s potential to improve the diagnostic accuracy of non-invasive diagnostic tests.The study showed that the addition of miRNA improved the detection of early-stage ovarian cancers and that diagnostic performance improved even further when using a combination of approaches, including miRNA, proteins, and metadata. 

Aspira Women's Health, Inc. - Two Important Announcements from Aspira Women's Health

<ul><li>Aspira Women’s Health announced it has named Jody Berry, Ph.D as its new Chief Scientific Officer.</li><li>Dr. Ryan Phan, who stepped down from the position, remains as an advisor through the end of the year to help with the transition and provide scientific and operational advice related to ongoing product development programs.</li><li>Dr. Berry is a recognized international expert in immunoassay development, antibody technology, and infectious diseases.</li></ul>

Aspira Women’s Health announced it has named Jody Berry, Ph.D as its new Chief Scientific Officer.Dr. Ryan Phan, who stepped down from the position, remains as an advisor through the end of the year to help with the transition and provide scientific and operational advice related to ongoing product development programs.Dr. Berry is a recognized international expert in immunoassay development, antibody technology, and infectious diseases.

Aspira Women's Health, Inc. - Announces New Chief Scientific Officer

<div><div><div><div><ul style="list-style-type: disc;"><li><p>Agreement with University of Oxford. On August 31, 2023, Aspira Women’s Health announced that it has entered into a material transfer agreement with the University of Oxford for the procurement of serum samples to be used to verify and validate AWH’s endometriosis blood testing algorithms.</p></li><li><p>This means that AWH will be able to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis.</p></li><li><p>Verifying the test. This involves taking a test and comparing known samples to run against the test, verifying the test actually works. </p></li></ul></div></div></div></div>

Agreement with University of Oxford. On August 31, 2023, Aspira Women’s Health announced that it has entered into a material transfer agreement with the University of Oxford for the procurement of serum samples to be used to verify and validate AWH’s endometriosis blood testing algorithms.This means that AWH will be able to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis.Verifying the test. This involves taking a test and comparing known samples to run against the test, verifying the test actually works. 

Aspira Women's Health, Inc. - Signs Exclusive Agreement with University of Oxford

<div><div><div><div><ul style="list-style-type: disc;"><li><p>Aspira Women’s Health reported in-line 2Q23 financial results. Revenues in the quarter were $2.5 million, below our estimate of $3.2 million.</p></li><li><p>EPS for the quarter was ($0.28), above our estimate of ($0.66).</p></li><li><p>AWH continues its good expense control, showing its ability to continue to grow revenue and test volumes, while keeping expenses well under control.</p></li></ul></div></div></div></div>

Aspira Women’s Health reported in-line 2Q23 financial results. Revenues in the quarter were $2.5 million, below our estimate of $3.2 million.EPS for the quarter was ($0.28), above our estimate of ($0.66).AWH continues its good expense control, showing its ability to continue to grow revenue and test volumes, while keeping expenses well under control.

Aspira Women's Health, Inc. - Reports In-Line 2Q23

United States

Aspira Women's Health Inc. operates as a biotech company. The Company develops and discovers testing and treatments for gynecologic issues. Aspira Women's Health serves customers in the State of Texas.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aspira Women's Health (AWH US)

Aspira Women's Health, Inc. - Reports 3Q23 Results

Revenue of $2.2 million was below our estimate, but good expense control is in place and is expected to continue.Our estimates for 2023 and 2024...

Water Tower Research

Aspira Women's Health, Inc. - Two Important Announcements from Aspira Women's Health

The study showed that the addition of miRNA improved the detection of early-stage ovarian cancers and that diagnostic performance improved even...

Water Tower Research

Aspira Women's Health, Inc. - Announces New Chief Scientific Officer

Aspira Women’s Health announced it has named Jody Berry, Ph.D as its new Chief Scientific Officer. Dr. Ryan Phan, who stepped down from the...

Water Tower Research

Aspira Women's Health, Inc. - Signs Exclusive Agreement with University of Oxford

This means that AWH will be able to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis...

Water Tower Research

Aspira Women's Health, Inc. - Reports In-Line 2Q23

Aspira Women’s Health reported in-line 2Q23 financial results. Revenues in the quarter were $2.5 million, below our estimate of $3.2 million.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)